Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Today’s guest on The Long Run podcast is Vicki Sato. She’s one of the biotech industry’s pioneers.
Sato started out as a classic academic scientist on the Harvard faculty. Beginning in the mid-1980s, and for about 20 years, the next phase of her career was as an executive at Biogen and Vertex Pharmaceuticals. Her fingerprints are all over a number of drugs that are linchpins for those companies today.
Vicki Sato
The last decade or so she’s been a teacher and mentor — on the Harvard Business School faculty and as a board member. As a director of Bristol-Myers Squibb, Denali Therapeutics and Vir Biotechnology, she oversees strategic direction of companies working on treatments for cancer, neurodegenerative disease, and infectious disease. Having been around for this many years, she’s wise. And tough. But she’s also a warm person who cares a lot about the next generation of biotech leaders. She splits her time now between Boston and New York. Fun fact: She says she’s enjoying the culture of the Big City and dances the tango – competitively.
It was a treat to sit down with her and discuss her career arc.
Before diving in, a word of thanks to the sponsors of the show: Presage Biosciences and Harvard Medical School executive education.
Next on The Long Run: Chad and Harlan Robins, the co-founders and brothers who run Seattle-based Adaptive Biotechnologies. This company has raised about $400 million over the years, and carved out a niche in immune sequencing, or immune profiling — a novel application of next-gen sequencing technology. We talked some about the science, the business strategy, and what it’s like to manage a company as brothers.
Now, join me and Vicki Sato for The Long Run.
Six months of hard training is in the bank. Tomorrow morning, I will lug a pair of 120-liter gear bags to the airport and get on the plane for Kathmandu.
Destination: Mt. Everest, 29,029 feet/8,848 meters. The summit of the highest mountain in the world.
No matter what happens, three things are certain: I’ve given it everything I’ve got to prepare physically and mentally. I’m in good hands with the guides at Alpine Ascents International. And I’m eternally grateful for all of your support for the Everest Climb to Fight Cancer campaign at Fred Hutch.
The fundraising total for cancer research stands at $329,110.
Thank you, thank you, thank you.
What can you expect between now and when I get home to the U.S. on June 2?
For more background on the Climb to Fight Cancer and the Everest expedition, check the links below.
http://engage.fredhutch.org/site/PageServer?pagename=2011climb_greeting
https://timmermanreport.com/everest-fundraiser-for-cancer-research/
Thank you to the folks at Fred Hutch, and a few special guests, for making this send-off video. I’ve really enjoyed working with you on this.
Keep pursuing your great adventures in biotech. — Luke
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
What a whirlwind last week was! The Seattle and Boston Cancer Summits were an East-West combo punch on behalf of the Everest Climb to Fight Cancer fundraising campaign for Fred Hutch.
These events did the job: Bringing together leading thinkers and doers on both coasts, they both drew sellout, highly engaged crowds. The fundraising tally now stands at $326,000!!
The weather forecast for a nor’easter in Boston made me a little nervous, but the snow didn’t interfere. Everything came off without a hitch. Both of these gatherings were brimming with ideas, positive energy toward tackling the challenges of cancer R&D, good humor, and well wishes about my upcoming summit bid on the world’s highest mountain.
Special thanks to the sponsors of this campaign that began in October:
Summit: Sanofi
South Col: 10X Genomics
Advanced Base Camp:
Alexandria Real Estate Equities
Takeda Pharmaceuticals
Khumbu Icefall: Novateur
Base Camp:
Sofinnova Ventures
5AM Ventures
ARCH Venture Partners
Alnylam Pharmaceuticals
EBD Group
Loncar Investments
Photo credit for the Boston Cancer Summit: David Parnes.
I also want to thank the great team of people who did so much work behind the scenes to make these events happen. At Fred Hutch in Seattle, that includes Cate Tambeaux, Kristin Nash, Kelly O’Brien, and Niki Robinson. At Sanofi Genzyme in Cambridge, special thanks go to Ashleigh Koss, Anna Robinson, and Christy Maginn.
Two from now, on Mar. 27, I will get on the plane for Nepal, and won’t be coming back from Everest until June 2. You can read FAQs about the expedition and donate to the campaign here if you haven’t already.
I’m feeling great physically, and privileged to be in position to do this climb and bring so much fundraising and attention to this moment of possibility in cancer research. Thanks to you being part of it.
Enjoy the photos!
BOSTON CANCER SUMMIT: MAR. 7, 2018
What a whirlwind last week was! The Seattle and Boston Cancer Summits were an East-West combo punch on behalf of the Everest Climb to Fight Cancer fundraising campaign for Fred Hutch.
These events did the job: Bringing together leading thinkers and doers on both coasts, they both drew sellout, highly engaged crowds. The fundraising tally now stands at $326,000!!
The weather forecast for a nor’easter in Boston made me a little nervous, but the snow didn’t interfere. Everything came off without a hitch. Both of these gatherings were brimming with ideas, positive energy toward tackling the challenges of cancer R&D, good humor, and well wishes about my upcoming summit bid on the world’s highest mountain.
Special thanks to the sponsors of this campaign that began in October:
Summit: Sanofi
South Col: 10X Genomics
Advanced Base Camp:
Alexandria Real Estate Equities
Takeda Pharmaceuticals
Khumbu Icefall: Novateur
Base Camp:
Sofinnova Ventures
5AM Ventures
ARCH Venture Partners
Alnylam Pharmaceuticals
EBD Group
Loncar Investments
Photo credits from the Seattle Cancer Summit were by Josh Belzman. Boston Cancer Summit photos were by David Parnes (see those in a separate post).
I also want to thank the great team of people who did so much work behind the scenes to make these events happen. At Fred Hutch in Seattle, that includes Cate Tambeaux, Kristin Nash, Kelly O’Brien, and Niki Robinson. At Sanofi Genzyme in Cambridge, special thanks go to Ashleigh Koss, Anna Robinson, and Christy Maginn.
Two from now, on Mar. 27, I will get on the plane for Nepal, and won’t be coming back from Everest until June 2. You can read FAQs about the expedition and donate to the campaign here if you haven’t already.
I’m feeling great physically, and privileged to be in position to do this climb and bring so much fundraising and attention to this moment of possibility in cancer research. Thanks to you being part of it.
SEATTLE CANCER SUMMIT: MAR.5, 2018
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Timmerman Report is bringing together major East Coast cancer R&D players for an intimate half-day event on March 7: the Boston Cancer Summit. Join an all-star gathering of pharma executives, hot startups, and VCs making things happen in the treatment and diagnosis of cancer.
Tickets are sold out. The conference will be at Sanofi Genzyme’s flagship building in the heart of Kendall Square. All proceeds go to a good cause: basic cancer research at the Fred Hutchinson Cancer Research Center, as part of my Everest Climb to Fight Cancer fundraising campaign.
We’ll talk about aiming for elusive cancer targets, where VCs see opportunities for investment, cancer diagnostics in the DNA information age, designing clinical trials for fast answers, and emerging modalities for cancer care. You’ll also see more than a few entrepreneurs who I consider to be newsmakers of tomorrow.
PROGRAM
1 pm. Registration and Networking.
1:30 pm Welcome Remarks. Luke Timmerman, founder of Timmerman Report. Kelly O’ Brien, VP of Philanthropy, Fred Hutchinson Cancer Research Center. Gary Nabel, Chief Scientific Officer and Senior Vice President of Sanofi.
1:40 pm
A series of five brief, 10-minute presentations from exciting East Coast drug developers working to fight cancer in their own way. They are:
2:40 pm
Kush Parmar, managing partner, 5AM Ventures
3:10 pm
3:40 pm
4:10 pm
Jay Bradner, president, Novartis Institutes for Biomedical Research
4:30 pm
Before the cocktail hour, I might have a couple minutes for a fun surprise to give you a taste of the Everest climb.
TIME: 12:30 p.m. to 6 p.m.
DATE: March 7
PLACE: Sanofi Genzyme, 500 Kendall St., Cambridge, MA
TICKETS:
At the Door: $350
Summit Sponsor:
South Col Sponsor:
Advanced Base Camp Sponsors:
Khumbu Icefall Sponsor:
Base Camp Sponsors:
